NCT04175470View on ClinicalTrials.gov

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

July 30, 2024

Study Completion Date

December 31, 2024

Conditions
Ovarian Cancer Recurrent
Interventions
DRUG

Bevacizumab

10 mg/kg intravenously every three weeks

DIETARY_SUPPLEMENT

Tocotrienol

Capsules, 300 mg orally three times daily

Trial Locations (1)

7100

Department of Oncology, Vejle Hospital, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT04175470 - Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter